Your browser is no longer supported. Please, upgrade your browser.
AXGT Axovant Gene Therapies Ltd. weekly Stock Chart
AXGT [NASD]
Axovant Gene Therapies Ltd.
Index- P/E- EPS (ttm)-2.92 Insider Own50.50% Shs Outstand37.71M Perf Week21.57%
Market Cap116.90M Forward P/E- EPS next Y-2.41 Insider Trans39.00% Shs Float18.02M Perf Month44.19%
Income-65.00M PEG- EPS next Q-0.61 Inst Own14.20% Short Float3.53% Perf Quarter-38.98%
Sales- P/S- EPS this Y51.40% Inst Trans89.70% Short Ratio2.66 Perf Half Y-45.23%
Book/sh0.22 P/B14.09 EPS next Y14.20% ROA-75.90% Target Price21.00 Perf Year-64.45%
Cash/sh0.74 P/C4.21 EPS next 5Y- ROE-241.60% 52W Range1.41 - 9.60 Perf YTD-39.45%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-67.71% Beta1.20
Dividend %- Quick Ratio1.10 Sales past 5Y- Gross Margin- 52W Low119.86% ATR0.32
Employees57 Current Ratio1.10 Sales Q/Q- Oper. Margin- RSI (14)60.06 Volatility12.38% 14.76%
OptionableYes Debt/Eq3.08 EPS Q/Q71.10% Profit Margin- Rel Volume1.18 Prev Close2.67
ShortableYes LT Debt/Eq1.30 EarningsFeb 06 Payout- Avg Volume238.67K Price3.10
Recom1.70 SMA2042.27% SMA50-0.39% SMA200-41.52% Volume281,043 Change16.10%
Oct-28-19Reiterated Chardan Capital Markets Buy $10 → $15
Aug-12-19Upgrade Robert W. Baird Neutral → Outperform $16 → $13
Jun-21-19Initiated SVB Leerink Outperform $18
Apr-12-19Initiated Evercore ISI Outperform
Mar-11-19Upgrade Chardan Capital Markets Neutral → Buy $4
Apr-08-20 12:00PM  All You Need to Know About Axovant (AXGT) Rating Upgrade to Buy Zacks +5.12%
08:00AM  Axovant Provides Business and Operations Update During the COVID-19 Pandemic GlobeNewswire
Mar-31-20 08:00AM  Axovant to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day GlobeNewswire
Mar-10-20 06:46AM  Does Market Volatility Impact Axovant Gene Therapies Ltd.'s (NASDAQ:AXGT) Share Price? Simply Wall St.
Feb-24-20 04:01PM  Axovant Gene Therapies Announces Closing of $74.7 Million Public Offering of Common Shares and Prefunded Warrants, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -7.17%
Feb-19-20 10:11PM  Axovant Gene Therapies Announces Pricing of $65 Million Public Offering GlobeNewswire
04:02PM  Axovant Gene Therapies Announces Commencement of Public Offering GlobeNewswire
Feb-10-20 06:00AM  Axovant Announces Financial Results for Third Fiscal Quarter and Nine Months Ended December 31, 2019 GlobeNewswire
Jan-13-20 06:30AM  Axovant Announces Positive 12-month Data on AXO-Lenti-PD and Provides Updates Across Gene Therapy Pipeline Programs GlobeNewswire
Jan-06-20 12:00PM  What Makes Axovant (AXGT) a New Buy Stock Zacks
Dec-23-19 02:19PM  Axovant Gene Therapies Ltd. (AXGT): Hedge Funds In Wait-and-See Mode Insider Monkey
Dec-20-19 08:12AM  The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering Benzinga
Dec-19-19 05:41PM  Axovant Provides Clinical Program Update for AXO-AAV-GM1, a Novel Investigational Gene Therapy for GM1 Gangliosidosis GlobeNewswire
Dec-03-19 07:00AM  Axovant Announces Amendment to Credit Facility with Hercules Capital GlobeNewswire
Nov-19-19 09:40AM  Axovant's GM1 Gangliosidosis Candidate Gets Orphan Drug Tag Zacks
Nov-18-19 07:30AM  Axovant Gene Therapies Receives Orphan Drug Designation from FDA for AXO-AAV-GM1 for the Treatment of GM1 Gangliosidosis GlobeNewswire
Nov-14-19 08:34AM  Axovant Gene Therapies Enters Oversold Territory Zacks
Nov-13-19 09:00AM  Axovant (AXGT) Moves to Strong Buy: Rationale Behind the Upgrade Zacks -5.74%
Nov-08-19 08:00AM  Axovant Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2019 GlobeNewswire -7.50%
Nov-05-19 08:00AM  Axovant Gene Therapies Announces Investor Conference Presentations for the Remainder of 2019 GlobeNewswire
Oct-23-19 07:00AM  Axovant Presents First Evidence of Clinical Stabilization in Tay-Sachs Disease at the European Society of Gene and Cell Therapy 27th Annual Congress GlobeNewswire +17.93%
Oct-20-19 08:08AM  The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict Benzinga
Oct-10-19 08:00AM  Axovant Gene Therapies Announces Upcoming Presentations at the European Society of Gene and Cell Therapy 27th Annual Congress GlobeNewswire +5.65%
Oct-09-19 09:00AM  Axovant (AXGT) Upgraded to Buy: Here's What You Should Know Zacks
Sep-27-19 05:45PM  Axovant (AXGT) Gains As Market Dips: What You Should Know Zacks
Sep-25-19 04:05PM  Axovant Gene Therapies to Present at 2019 Cell & Gene Meeting on the Mesa GlobeNewswire
Sep-19-19 05:50PM  Axovant (AXGT) Stock Moves -1.31%: What You Should Know Zacks
Sep-13-19 05:45PM  Axovant (AXGT) Gains As Market Dips: What You Should Know Zacks
Sep-12-19 09:15AM  Axovant Gene Therapies Ltd. (NASDAQ:AXGT): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Aug-12-19 05:48PM  Axovant Analyst Turns Bullish Ahead Of Q4 Gene Therapy Data Readouts Benzinga
Aug-09-19 07:00AM  Axovant Announces Corporate Updates and Financial Results for First Fiscal Quarter Ended June 30, 2019 GlobeNewswire
Aug-08-19 10:45AM  Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2 Zacks
10:15AM  Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates Zacks
09:26AM  Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates Zacks
Aug-02-19 10:48AM  Geron (GERN) Stock Up Despite Q2 Earnings & Sales Miss Zacks -6.31%
10:43AM  IVERIC bio's (ISEE) Q2 Loss Narrows, Gene Therapy in Focus Zacks
10:04AM  Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down Zacks
Jul-29-19 05:50PM  Axovant (AXGT) Gains As Market Dips: What You Should Know Zacks
11:40AM  Axovant (AXGT) to Post Q1 Earnings: What's in the Cards? Zacks
Jul-16-19 08:17AM  Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall Zacks
Jul-12-19 05:45PM  Axovant (AXGT) Outpaces Stock Market Gains: What You Should Know Zacks
Jul-10-19 07:04AM  Will Axovant Sciences Continue to Surge Higher? Zacks
Jul-08-19 09:55AM  Sarepta Stock Up Almost 40% This Year So Far: Here's Why Zacks
Jul-03-19 02:19PM  Perrigo Completes Ranir Acquisition, Raises '19 Guidance Zacks
Jul-01-19 07:00AM  Axovant Appoints David Nassif as Chief Financial Officer and Expands Board of Directors GlobeNewswire
Jun-28-19 08:35PM  Is Axovant Gene Therapies Ltd. (AXGT) Going to Burn These Hedge Funds? Insider Monkey
Jun-26-19 08:58AM  Are Options Traders Betting on a Big Move in Axovant (AXGT) Stock? Zacks
Jun-24-19 07:01AM  Axovant Announces Poster Presentations at the 5th Congress of the European Academy of Neurology GlobeNewswire -6.56%
Jun-21-19 03:35PM  Axovant Gene Therapies News: AXGT Stock Soars on Manufacturing Deal InvestorPlace +18.48%
10:34AM  Options Heat Up on "Undervalued" Drug Stock Schaeffer's Investment Research
Jun-20-19 09:42AM  Axovant Strikes Gene Therapy Manufacturing Partnership With CDMO Benzinga
07:00AM  Axovant and Yposkesi Sign Strategic Gene Therapy Development and Manufacturing Partnership GlobeNewswire
Jun-14-19 09:00AM  Axovant (AXGT) Upgraded to Strong Buy: Here's Why Zacks +5.57%
Jun-11-19 06:18PM  Novavax' Shares Drop as FDA Advises Another Study for Resvax Zacks
04:05PM  Axovant Announces Financial Results and Corporate Updates for Fourth Quarter and Fiscal Year Ended March 31, 2019 GlobeNewswire
Jun-06-19 07:40AM  Axovant Announces 6-Month Follow-Up Data From First Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD and Pipeline Update GlobeNewswire -16.45%
Jun-04-19 04:16PM  bluebird's Zynteglo Gets EU Conditional Marketing Approval Zacks
May-31-19 07:00AM  Axovant to Present at Upcoming Conferences in June GlobeNewswire -5.58%
May-30-19 08:44AM  Fibrocell Up on FDA Designation for Gene Therapy Candidate Zacks
May-29-19 10:40AM  Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down Zacks
May-28-19 09:02AM  Epizyme (EPZM) Shares Surge More Than 100% YTD: Here's Why? Zacks
May-27-19 05:00AM  Dynavax (DVAX) to Cut Jobs and Focus on Vaccine Business Zacks
May-21-19 05:34AM  Axovant Sciences Enters Oversold Territory Zacks
May-20-19 03:06PM  Dr. Reddy's (RDY) Q4 Earnings Up Y/Y, Revenues Top Estimates Zacks
07:00AM  Axovant to Present at 2019 RBC Capital Markets Global Healthcare Conference GlobeNewswire
May-17-19 05:33PM  NIH administers first clinical trial treatment for GM1 created by Auburn, UMass PR Newswire
May-16-19 04:05PM  Axovant Announces Dosing of First Patient in Clinical Program for AXO-AAV-GM1, a Novel Gene Therapy for GM1 Gangliosidosis GlobeNewswire
May-14-19 09:05AM  Regeneron (REGN) Gets FDA Nod for Eylea Label Expansion Zacks
May-07-19 04:15PM  Axovant Announces Reverse Share Split Effectiveness GlobeNewswire
Apr-30-19 07:00AM  Axovant Announces Dosing of First Patient in Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD GlobeNewswire
Apr-25-19 02:35PM  Imagine Owning Axovant Gene Therapies (NASDAQ:AXGT) And Trying To Stomach The 91% Share Price Drop Simply Wall St. -6.90%
Apr-16-19 07:00AM  Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy GlobeNewswire
Apr-10-19 09:00AM  Axovant (AXGT) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Apr-05-19 07:48AM  The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership Benzinga
Apr-04-19 04:10PM  Axovant Announces Plan to Effect Reverse Share Split GlobeNewswire
Mar-29-19 07:00AM  Axovant Announces Clinical Updates from AXO-AAV-GM2 and AXO-Lenti-PD Studies GlobeNewswire
Mar-18-19 07:45AM  Axovant Sciences Gene Therapy Showing Progress, Pipeline Review ACCESSWIRE
Mar-14-19 11:02AM  Here's Why Axovant Gene Therapies Dropped as Much as 16.6% Today Motley Fool -18.86%
07:00AM  Axovant Sciences Announces Pricing of $40 Million Public Offering of Common Shares GlobeNewswire
Mar-13-19 04:21PM  Axovant Sciences Announces Public Offering of Common Shares GlobeNewswire
Mar-11-19 01:38PM  Axovant Shares Surge On Positive Results For Parkinson's, Tay-Sachs Gene Therapies Benzinga +14.19%
01:16PM  Here's Why Axovant Gene Therapies Rocketed Higher Today Motley Fool
09:35AM  Four Healthcare Stocks Making Moves on Monday ACCESSWIRE
06:30AM  Axovant Reports Positive Interim Results From First Cohort Of SUNRISE-PD Phase 2 Trial Of AXO-Lenti-PD Gene Therapy In Parkinsons Disease GlobeNewswire
06:30AM  Axovant Announces Clinical Update From First Tay-Sachs Disease Patient Dosed With AXO-AAV-GM2 Gene Therapy GlobeNewswire
Mar-04-19 07:00AM  Axovant to Present at Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Feb-21-19 09:08AM  Have Insiders Been Buying Axovant Sciences Ltd. (NASDAQ:AXGT) Shares This Year? Simply Wall St.
08:00AM  Axovant to Host First R&D Day March 29, 2019 GlobeNewswire
Feb-19-19 07:00AM  Axovant to Present at 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, and Parkinson's diseases. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Gene Therapies Ltd. is a subsidiary of Roivant Sciences Ltd.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pande AtulDirectorMar 16Buy1.7810,00017,84413,370Mar 18 08:20 PM
Roivant Sciences Ltd.10% OwnerFeb 24Buy3.755,333,33319,999,99918,577,380Feb 27 07:49 PM